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Introduction
Cognitive problems are prevalent and disabling in 
patients with multiple sclerosis (MS).1 Early detec-
tion is therefore highly relevant. However, cognitive 
problems are difficult to detect during routine neuro-
logical care due to their subtle nature and weak rela-
tion with physical disabilities.1 Neuropsychological 
evaluation is a useful tool to assess cognitive prob-
lems, and concise neuropsychological batteries are 
available for MS patients (e.g. Rao’s Brief Repeatable 
Neuropsychological Battery (BRB-N)2 and the Brief 
International Cognitive Assessment for MS 
(BICAMS)).3 However, it is not feasible for all health-
care facilities to routinely perform neuropsychologi-
cal evaluations during neurological care visits. In 
order to identify patients who may benefit most from 
neuropsychological evaluation, it is essential to know 
the clinical value of patient-reported cognitive 
complaints.
A brief self-report questionnaire to identify cognitive 
and neurobehavioral problems is the MS Neuro-
psychological Screening Questionnaire (MSNQ).4 The 
informant version of the MSNQ (MSNQ-I) is consid-
ered a reliable cognitive screening tool,4–7 but inform-
ants do not generally accompany MS patients at 
routine neurological care visits. The clinical value of 
the patient-reported MSNQ (MSNQ-P) varied across 
studies,4–7 which may be due to small sample sizes or 
differences in cognitive classification methods. 
Importantly, psychological factors seem to play an 
important role in patient-reported cognitive com-
plaints and should therefore be taken into account.4–7
This study aimed to extend on previous work by 
investigating the clinical applicability of the MSNQ-P.
Materials and methods
Participants
We selected 352 patients from the Amsterdam MS 
cohort (65.9% female, age: 50.7 ± 11.8 years, disease 
duration: 16.8 ± 9.1 years and phenotype: clinically 
isolated syndrome (6.0%), relapsing–remitting 
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(58.5%), secondary progressive (20.2%), primary 
progressive (10.5%) or unknown (4.8%)). The 
patients (1) completed the MSNQ-P (≤1 missing 
item), (2) had scores on all cognitive domains of the 
neuropsychological examination and (3) their visit 
was not included in our previous study6 to ensure 
independence between studies. A total of 88 matched 
healthy controls (HCs) were also included.
Outcomes
The MSNQ-P measured subjective cognitive com-
plaints4 and is validated in a Dutch MS population.6 
Scores range from 0 to 60 and higher scores indicate 
more cognitive complaints. The Hospital Anxiety and 
Depression Scale measured anxiety and depression,8 
the Checklist Individual Strength-20-R measured 
fatigue,9 and the Expanded Disability Status Scale 
indicated neurological disability. An extended ver-
sion of the BRB-N measured cognitive functioning,2 
including verbal memory, visuospatial memory, infor-
mation processing speed, attention, working memory, 
executive function and verbal fluency. Scores were 
corrected for age, education and gender and trans-
formed into domain-specific z-scores based on HC 
scores. Patients were classified as (1) cognitively 
impaired (CI; ≥2 SDs below HCs on ≥2 domains), (2) 
mildly cognitively impaired (MCI; ≥1.5 SDs below 
HCs on ≥2 domains and not CI or ≥2 SDs below HCs 
on 1 domain and <1.5 SDs on the other domains) and 
(3) cognitively preserved (CP; remainder).
Statistical analyses
We performed receiver operating characteristic 
(ROC) analyses and Bayesian statistics to determine 
the optimal cut-off scores (i.e. the highest value for 
sensitivity and specificity combined) and clinically 
relevant score ranges. Logistic regression analyses 
were performed to correct for depression, anxiety and 
fatigue. To identify relevant predictors of MSNQ-P 
scores, two backward linear regression models were 
performed including (1) cognition, depression, anxi-
ety, fatigue, age, disease duration, education and neu-
rological disability (complete data were available for 
245 patients) and (2) domain-specific cognitive 
z-scores (p < 0.05).
Results
The optimal cut-off scores and psychometric proper-
ties are presented in Table 1. The optimal cut-off score 
to screen for CI or both MCI and CI resulted in an 
area under the curve (AUC) of 0.61 and 0.64, respec-
tively. The AUCs did not increase when correcting for 
depression (0.63 and 0.66, respectively), anxiety 
(0.62 and 0.63, respectively), or fatigue (0.59 and 
0.59, respectively). The AUCs also did not increase 
when neurobehavioral MSNQ-P items (13–15) were 
excluded (0.61 and 0.63, respectively). Since 
MSNQ-P scores were related to education, we per-
formed stratified analyses for education (see 
Supplementary Table 1). The AUCs were higher 
among patients with a higher education (0.68 and 
0.69, respectively), compared to a middle (0.50 and 
0.55, respectively) or lower education (0.58 and 0.56, 
respectively). In patients with a higher education, the 
optimal cut-off score to screen for CI and for both 
MCI and CI was 12, which corresponded to a high 
sensitivity (0.87 and 0.85, respectively) and negative 
predictive value (0.93 and 0.81, respectively), yet a 
relatively lower specificity (0.40 and 0.52, respec-
tively) and positive predictive value (0.25 and 0.59, 
respectively). Figure 1 shows the distribution of 
MSNQ-P scores and clinically relevant score ranges.
The final backward regression model showed that 
cognition (MCI vs CP: beta = 0.13, p = 0.020; CI vs 
CP: beta = 0.12, p = 0.045), depression (beta = 0.20, 
p = 0.008), anxiety (beta = 0.19, p = 0.006), fatigue 
(beta = 0.39, p < 0.001), education (middle vs low: 
beta = −0.16, p = 0.008; high vs low: beta = −0.14, 
Table 1. MSNQ-P cut-off scores and psychometric properties.
Cut-offa Sensitivity Specificity PPV NPV Accuracyb AUC
CI vs MCI and CP 18 0.66 0.51 0.31 0.81 0.55 0.61*
CI and MCI vs CP 12 0.82 0.40 0.66 0.62 0.65 0.64*
CI: cognitively impaired; MCI: mildly cognitively impaired; CP: cognitively preserved; PPV: positive predictive value; NPV: 
negative predictive value; AUC: area under the curve.
aOptimal cut-off score on the patient-reported Multiple Sclerosis Neuropsychological Questionnaire (MSNQ-P) to detect the 
cognitively impaired patient group (either CI or a combination of both CI and MCI patients).
bProportion of patients correctly classified as cognitively impaired and cognitively preserved.
*Significantly different from 0.50 (p < 0.01).
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p = 0.027) and neurological disability (middle vs low: 
beta = −0.04, p = 0.441; high vs low: beta = −0.17, 
p = 0.004) independently predicted MSNQ-P scores 
(R2 = 0.49). In terms of cognitive domains, visuospa-
tial memory (beta = −0.12, p = 0.026) and attention 
(beta = −0.24, p < 0.001) predicted MSNQ-P scores 
(R2 = 0.08).
Discussion
The optimal MSNQ-P cut-off scores to identify cog-
nitive impairment had insufficient psychometric prop-
erties, which is in line with most previous studies.5–7 
Our findings do indicate that certain score ranges are 
clinically relevant. High MSNQ-P scores (≥27) indi-
cated mild or severe cognitive impairment in 71% of 
the cases, and we advise neuropsychological evalua-
tion when MS patients obtain these scores. Very low 
MSNQ-P scores (≤5) indicated intact cognitive func-
tion, but we consider this range too small to be clini-
cally relevant. Interestingly, MSNQ-P scores were a 
better reflection of cognitive status among patients 
with a higher education than among patients with a 
middle or lower education. For patients with a higher 
education, MSNQ-P scores below 12 indicated intact 
cognitive function. Thus, the MSNQ-P can be clini-
cally useful when interpreting low or high score ranges.
Multiple factors influenced patient-reported cognitive 
complaints, which may explain the difficulty of defining 
specific and sensitive cut-off scores. Cognitive func-
tion itself, but also depression, anxiety, fatigue, edu-
cation and neurological disability predicted MSNQ-P 
scores. Benedict et al. argued that the MSNQ-P might 
be a useful screening tool when combined with a 
depression questionnaire.4 However, the ability of the 
MSNQ-P to screen for cognitive impairment did not 
improve when we excluded patients with a depressed 
mood (data not shown). In general, the clinical appli-
cability did not improve when either depression, anxi-
ety or fatigue was taken into account.
A promising line of research focuses on short neu-
ropsychological tests as a cognitive screening tool 
(e.g. the Symbol Digit Modalities Test),10 which may 
reflect cognitive impairment more accurately. 
However, the need for guided assistance in adminis-
tration could challenge implementation in routine 
neurological care.
To conclude, MSNQ-P scores in the lowest and high-
est ranges can indicate whether patients are cogni-
tively intact or impaired. Still, patient-reported 
cognitive complaints assessed by the MSNQ-P should 
be interpreted with caution.
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Figure 1. Distribution of MSNQ-P scores across the cognitive groups. The bold lines represent the means and SDs 
(*p < 0.001). Of all patients, 41.8% were categorized as CP (n = 147), 32.7% as MCI (n = 115), and 25.6% as CI (n = 90). 
(a) The CI and MCI groups both had significantly higher MSNQ-P scores than the CP group. (b) The CI and MCI groups 
combined had significantly higher MSNQ-P scores than the CP group. The dotted lines indicate the clinically relevant 
score ranges (defined as a positive predictive value (PPV) or negative predictive value (NPV) of at least 0.70). The upper 
line indicates that 71% of the patients with scores of 27 or higher were MCI or CI patients. The lower line indicates that 
70% of the patients with scores of 5 or lower were CP patients.
CP: cognitively preserved; MCI: mildly cognitively impaired; CI: cognitively impaired.
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